Cite

    Carlos Taxonera et al.. “Early dose optimization of golimumab induces late response and long-term clinical benefit in moderately to severely active ulcerative colitis.” Current medical research and opinion, vol. 35, 2019, pp. 1297–1304. http://access.bl.uk/ark:/81055/vdc_100086223122.0x00004e